Active surveillance for low-risk prostate cancer

Current Urology Reports
L Klotz

Abstract

There is ample evidence that low risk and many cases of low-/intermediate-risk prostate cancer, are indolent, have little or no metastatic potential, and do not pose a threat to the patient in his lifetime. Major strides have been made in understanding who these patients are and in encouraging the use of conservative management in such individuals. A component of conservative management is the early identification of those 'low-risk' patients who harbour higher risk disease, and benefit from definitive therapy. This represents about 30% of newly diagnosed low-risk patients. A further small proportion of patients with low-risk disease demonstrate biological progression to higher grade disease. Men with lower risk disease can defer treatment, in most cases for life. Men with higher risk disease that can be localized to a relatively small volume of the prostate can undergo selective therapy. The results of active surveillance, embodying conservative management with selective delayed intervention for the subset who are re-classified as higher risk overtime based on repeat biopsy, imaging or biomarker results have shown that this approach is safe in the intermediate to long term, with a 3% cancer specific mortality at 10-15 years. F...Continue Reading

References

Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Mar 17, 2004·The Journal of Urology·Manish I PatelPeter T Scardino
Jun 10, 2004·JAMA : the Journal of the American Medical Association·Jan-Erik JohanssonHans-Olov Adami
Jul 11, 2006·Proceedings of the National Academy of Sciences of the United States of America·Lawrence TruePeter S Nelson
Dec 19, 2006·Nature Genetics·Scott A TomlinsArul M Chinnaiyan
Dec 14, 2007·Cell Cycle·Etsuo Susaki, Keiichi I Nakayama
Feb 15, 2008·Japanese Journal of Clinical Oncology·Yoshiyuki KakehiMasashi Niwakawa
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew J VickersHans Lilja
Aug 29, 2009·World Journal of Urology·Andreas ErbersdoblerAlexander Haese
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurence KlotzAndrew Loblaw
Mar 20, 2010·Nature·Manuel Serrano
Dec 2, 2010·JAMA : the Journal of the American Medical Association·Julia H HayesPamela M McMahon
Jan 18, 2011·The Journal of Urology·Scott E EggenerAndrew J Stephenson
Mar 2, 2011·The Prostate·Ashley E RossEdward M Schaeffer
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Apr 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey J TosoianH Ballentine Carter
Apr 12, 2011·TheScientificWorldJournal·Eggener Scott
Jun 3, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sima P PortenPeter R Carroll
Feb 4, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Tarek A BismarBryan Donnelly
Apr 26, 2012·The American Journal of Surgical Pathology·Hillary M RossJonathan I Epstein
May 4, 2012·The New England Journal of Medicine·Atul Gawande
Jun 8, 2012·Cancer·Adam C ReeseMatthew R Cooperberg
Nov 3, 2012·The Lancet Oncology·Hashim Uddin AhmedMark Emberton
Nov 20, 2012·European Urology·Meelan BulMonique J Roobol
Dec 4, 2012·Cancer Research·Adam G SowalskySteven P Balk
Mar 12, 2013·European Urology·Elizabeth D SelvaduraiChris C Parker
Jun 19, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Debasish SundiEdward M Schaeffer
Jul 13, 2013·Journal of the National Cancer Institute·Alexandre R ZlottaTheodorus H van der Kwast
Oct 19, 2013·The Journal of Clinical Investigation·Michael C HaffnerSrinivasan Yegnasubramanian
Jan 15, 2014·European Urology·Christopher E BarbieriMark A Rubin
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HaffnerH Ballentine Carter

❮ Previous
Next ❯

Citations

Nov 28, 2015·Surgical Pathology Clinics·Mark Pomerantz
Apr 3, 2016·Urologic Oncology·Kristen R Scarpato, Daniel A Barocas
Nov 23, 2015·American Journal of Preventive Medicine·Ingrid J Hall, Judith Lee Smith
Apr 3, 2016·International Journal of Cancer. Journal International Du Cancer·Friederike KendelWolfgang Gaissmaier
Nov 24, 2016·Oncotarget·Martina KluthRonald Simon
Jun 29, 2016·Prostate Cancer and Prostatic Diseases·A D VandersluisV Venkateswaran
Jan 18, 2019·JCO Clinical Cancer Informatics·Cédric M PanjePaul M Putora

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Risk Prediction

Cardiovascular risk prediction models based on classical risk factors identified in epidemiological studies are useful in primary prevention of cardiovascular disease in individuals. Here is the latest research.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.